Search results
Most guidelines for the management of patients with cardiovascular disease recommend angiotensin-converting enzyme (ACE) inhibitors as first-choice therapy, whereas angiotensin receptor blockers (ARBs) are merely considered an alternative for ACE inhibitor–intolerant patients.
ACE inhibitors and ARBs act by blocking RAAS with beneficial effects on patients with cardiovascular risk factors only (hypertension, diabetes) and with several heart diseases (heart failure, coronary artery disease).
31 lip 2023 · Objectives: Identify the mechanism of action of ACE inhibitors. Summarize monitoring/follow-up for patients initiated on ACE inhibitor therapy. Review the dosing parameters adjusting or replacing ACE inhibitor therapy based on adverse events or inadequate therapeutic response.
26 cze 2023 · ACE inhibitors are competitive inhibitors of ACE, which prevent the conversion of angiotensin I to angiotensin II. Angiotensin II acts as a potent vasoconstrictor that, when inhibited, can reduce blood pressure by dilating vessels and decreasing aldosterone secretion.
Angiotensin-converting enzyme (ACE) inhibitors are a classification of drugs that block the body’s production of angiotensin II. Angiotensin II induces oxidative stress and inflammation of cardiac tissue, which contributes to adverse remodeling processes.
12 kwi 2020 · This clinical transformation started just over 50 years ago, with the unexpected identification of a bradykinin‐potentiating peptide from snake venom, as a potent inhibitor of ACE which led to the development of the first synthetic inhibitor, captopril, followed by the angiotensin receptor blockers.
14 kwi 1998 · Clinical studies will compare the efficacy of ACE inhibitors and specific AT 1 receptor antagonists in the treatment of cardiovascular and renal disease. Finally, studies will determine to what extent individual characteristics such as race and ACE genotype determine responses to ACE inhibitors.
